Benjamin P. Saylor
Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.
Protein may be marker for aggressive prostate cancer
British scientists have discovered that the presence of a specific protein can distinguish between indolent and aggressive prostate cancer.
Urinary tract infection agent yields positive phase III study results
Ceftolozane/tazobactam, an investigational antibiotic, showed positive top-line results in a pivotal phase III clinical trial of the drug’s use in complicated urinary tract infections, Cubist Pharmaceuticals, Inc. reported.
December 2013 Urology Products and Services
The latest products and services from Mission Pharmacal, Eli Lilly, Richard Wolf Medical Instruments Corp., and Inspire on Purpose Publishing.
Newer prostate cancer agent slows progression in phase II trial
An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has metastasized to the bones, according to a recent analysis.
Insurance coverage expands for prostate cancer test
GenomeDx Biosciences has entered into contractual agreements for diagnostic laboratory testing as a participating provider that will expand insurance coverage for the company’s Decipher test for prostate cancer.
High, low testosterone levels linked to higher mortality risk
High, low testosterone levels linked to higher mortality risk
Older men with midrange testosterone levels tend to live longer compared with men who have low or high levels, Australian researchers say.
Trial to evaluate continued advanced prostate cancer treatment
Astellas Pharma US, Inc. and Medivation, Inc. have initiated a phase IV trial to evaluate the benefit of continued treatment with enzalutamide (Xtandi) beyond disease progression in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Study clarifies role of midstream cultures in UTI
The use of voided midstream urine cultures in diagnosing cystitis has limited value but can be modified to avoid undertreatment and inappropriate treatment, according to a recently published study.
Testosterone therapy may raise MI, stroke risk
Among a group of men who underwent coronary angiography and had a low serum testosterone level, the use of testosterone therapy was associated with increased risk of death, heart attack, or ischemic stroke, according to a recent study.
Prostate cancer screening on ASCO Choosing Wisely list
Prostate cancer has made its way into another set of Choosing Wisely recommendations, this time from the American Society of Clinical Oncology.